Gastrointestinal Tract Cancer - Pipeline Review, H2 2013


#173783

71pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Gastrointestinal Tract Cancer Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Gastrointestinal Tract Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastrointestinal Tract Cancer. Gastrointestinal Tract Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Gastrointestinal Tract Cancer.
  • A review of the Gastrointestinal Tract Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Gastrointestinal Tract Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Tract Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Gastrointestinal Tract Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Gastrointestinal Tract Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Gastrointestinal Tract Cancer 8
Gastrointestinal Tract Cancer Therapeutics under Development by Companies 10
Gastrointestinal Tract Cancer Therapeutics under Investigation by Universities/Institutes 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Gastrointestinal Tract Cancer Therapeutics - Products under Development by Companies 16
Gastrointestinal Tract Cancer Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in Gastrointestinal Tract Cancer Therapeutics Development 18
AstraZeneca PLC 18
Nektar Therapeutics 19
Millennium Pharmaceuticals, Inc. 20
Quest PharmaTech Inc. 21
BioAlliance Pharma SA 22
MabVax Therapeutics, Inc. 23
RaQualia Pharma Inc. 24
Gastrointestinal Tract Cancer - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
vandetanib - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
etirinotecan pegol - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
irinotecan hydrochloride - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
itriglumide - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SL-052 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
RQ-00000008 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
NEO-201 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
TALL-104 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
5B1 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
MLN-0264 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
grapiprant - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Drug Targeting c-Kit - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Gastrointestinal Tract Cancer Therapeutics - Drug Profile Updates 52
Gastrointestinal Tract Cancer Therapeutics - Discontinued Products 60
Gastrointestinal Tract Cancer Therapeutics - Dormant Products 61
Gastrointestinal Tract Cancer - Product Development Milestones 62
Featured News & Press Releases 62
Apr 01, 2013: Indian Supreme Court Denies Patent For Novartis's Updated Version Of Leukemia Drug Glivec 62
Apr 01, 2013: Supreme Court Denial Of Glivec Patent Clarifies Limited Intellectual Property Protection And Discourages Future Innovation In India, Novartis Says 62
Jun 05, 2012: AB Science Announces Publication Of Three ASCO Presentations Detailing Results Of Masitinib In Treatment Of Advanced GIST 63
Feb 01, 2012: Niiki Pharma Forms Scientific Advisory Board, To Focus On Anti-cancer Compound NKP-1339 64
Apr 01, 2011: Neogenix Oncology To Present Data On NEO-201 At AACR’s 2011 Annual Symposium 65
Jan 21, 2011: AVEO's Tivozanib Clinical Data To Be Presented At 2011 ASCO Gastrointestinal Cancers Symposium 66
Jan 12, 2011: Medimmune And Micromet Initiate Phase I Trial Of MT111 In Advanced Gastrointestinal Cancers 67
Nov 18, 2010: AVEO's Tivozanib In Combination With FOLFOX6 Demonstrates Anti-tumor Activity And Safety In Advanced Gastrointestinal Cancers 67
Oct 11, 2010: Micromet Announces FDA Acceptance Of IND For BiTE Antibody MT111/MEDI-565 68
Nov 03, 2008: Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN And Docetaxel Results at iSBTc Annual Meeting For The Trial REO 010 69

Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 71
Disclaimer 71

Number of Products Under Development for Gastrointestinal Tract Cancer, H2 2013 8
Products under Development for Gastrointestinal Tract Cancer - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Clinical Stage Development, H2 2013 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 17
AstraZeneca PLC, H2 2013 18
Nektar Therapeutics, H2 2013 19
Millennium Pharmaceuticals, Inc., H2 2013 20
Quest PharmaTech Inc., H2 2013 21
BioAlliance Pharma SA, H2 2013 22
MabVax Therapeutics, Inc., H2 2013 23
RaQualia Pharma Inc., H2 2013 24
Assessment by Monotherapy Products, H2 2013 25
Assessment by Stage and Route of Administration, H2 2013 27
Assessment by Stage and Molecule Type, H2 2013 29
Gastrointestinal Tract Cancer Therapeutics - Drug Profile Updates 52
Gastrointestinal Tract Cancer Therapeutics - Discontinued Products 60
Gastrointestinal Tract Cancer Therapeutics - Dormant Products 61
Number of Products under Development for Gastrointestinal Tract Cancer, H2 2013 8
Products under Development for Gastrointestinal Tract Cancer - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Products under Investigation by Universities/Institutes, H2 2013 12
Mid Clinical Stage Products, H2 2013 13
Early Clinical Stage Products, H2 2013 14
Discovery and Pre-Clinical Stage Products, H2 2013 15
Assessment by Monotherapy Products, H2 2013 25
Assessment by Route of Administration, H2 2013 26
Assessment by Stage and Route of Administration, H2 2013 27
Assessment by Molecule Type, H2 2013 28
Assessment by Stage and Molecule Type, H2 2013 29